The Role of Cytokines in the Pathogenesis of Endocrine Disease

Canadian Journal of Diabetes

Volumn 28, Issue 1, 2004, Pages 30-42

  Gianoukakis, Andrew G ^b   Smith, Terry J ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

Autoimmune disease; Beta cell; Bone metabolism; Cytokine; Lymphocyte; Thyroid function

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5;

BONE METABOLISM; CYTOKINE PRODUCTION; ENDOCRINE DISEASE; ENDOCRINE OPHTHALMOPATHY; EUTHYROID SICK SYNDROME; HASHIMOTO DISEASE; HELPER CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 1642401855     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Kakucska I, Romero LI, Clark BD, et al. Suppression of thyrotropin-releasing hormone gene expression by interleukin-1β in the rat: implications for nonthyroidal illness. Neuroendocrinology. 1994;59:129-137.
2. Wassen FW, Moerings EP, Van Toor H, et al. Effects of interleukin-1β on thyrotropin secretion and thyroid hormone uptake in cultured rat anterior pituitary cells. Endocrinology. 1996;137:1591-1598.
3. Dubuis JM, Dayer JM, Siegrist-Kaiser CA, et al. Human recombinant interleukin-113 decreases plasma thyroid hormone and thyroid stimulating hormone levels in rats. Endocrinology. 1988;123:2175-2181.
4. Hermus RM, Sweep CG, van der Meer MJ, et al. Continuous infusion of interleukin-1β induces a nonthyroidal illness syndrome in the rat. Endocrinology. 1992;131:2139-2146.
5. Rettori V, Jurcovicova J, McCann SM. Central action of interleukin-1 in altering the release of TSH, growth hormone, and prolactin in the male rat. J Neurosci Res. 1987;18:179-183.
6. Bartalena L, Grasso L, Brogioni S, et al. Interleukin 6 effects on the pituitary-thyroid axis in the rat. Eur J Endocrinol. 1994;131:302-306.
7. Lyson K, McCann SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology. 1991;54:262-266.
8. Ozawa M, Sato K, Han DC, et al. Effects of tumor necrosis factor-α/cachectin on thyroid hormone metabolism in mice. Endocrinology. 1988;123:1461-1467.
9. Rettori V, Milenkovic L, Beutler BA, et al. Hypothalamic action of cachectin to alter pituitary hormone release. Brain Res Bull. 1989;23:471-475.
10. Ongphiphadhanakul B, Fang SL, Tang KT, et al. Tumor necrosis factor-alpha decreases thyrotropin-induced 5′-deiodinase activity in FRTL-5 thyroid cells. Eur J Endocrinol. 1994;130:502-507.
11. Pekary AE, Berg L, Santini F, et al. Cytokines modulate type I iodothyronine deiodinase mRNA levels and enzyme activity in FRTL-5 rat thyroid cells. Mol Cell Endocrinol. 1994;101:R31-R35.
12. Yu J, Koenig RJ. Regulation of hepatocyte thyroxine 5′-deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome. J Biol Chem. 2000;275:38296-38301.
13. Molnár I, Balázs C, Szegedi G, et al. Inhibition of type 2,5′-deiodinase by tumor necrosis factor alpha, interleukin-6 and interferon gamma in human thyroid tissue. Immunol Lett. 2002;80:3-7.
14. Nagaya T, Fujieda M, Otsuka G, et al. A potential role of activated NF-κB in the pathogenesis of euthyroid sick syndrome. J Clin Invest. 2000;106:393-402.
15. Bartalena L, Brogioni S, Grasso L, et al. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness. J Endocrinol Invest. 1994;17:269-274.
16. Kimura T, Kanda T, Kotajima N, et al. Involvement of circulating interleukin-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. Eur J Endocrinol. 2000;143:179-184.
17. 3 concentration and serum IL-6 rise and TNFα in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab. 2001;86:4198-4205.
18. Corssmit EP, Heyligenberg R, Endert E, et al. Acute effects of interferon-α administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab. 1995;80:3140-3144.
19. van der Poll T, Romijn JA, Wiersinga WM, et al. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab. 1990;71:1567-1572.
20. Stouthard JM, van der Poll T, Endert E, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab. 1994;79:1342-1346.
21. Chopra IJ, Sakane S, Teco GN. A study of the serum concentration of tumor necrosis factor-α in thyroidal and nonthyroidal illnesses. J Clin Endocrinol Metab. 1991;72:1113-1116.
22. Boelen A, Platvoet-ter Schiphorst MC, Wiersinga WM. Immunoneutralisation of interleukin 1 (IL-1), tumor necrosis factor (TNFalpha), interleukin 6 (IL-6) or interferon (IFNgamma) does not prevent the LPS-induced sick euthyroid syndrome in mice. J Endocrinol. 1997;153:115-122.
23. van der Poll T, Van Zee KJ, Endert E, et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab. 1995;80:1341-1346.
24. van der Poll T, Endert E, Coyle SM, et al. Neutralization of TNF does not influence endotoxin-induced changes in thyroid hormone metabolism in humans. Am J Physiol. 1999;276:R357-R362.
25. Boelen A, Maas MA, Lowik CW, et al. Induced illness in interleukin-6 (IL-6) knock-out mice: a causal role of IL-6 in the development of the low 3,5,3′-triiodothyronine syndrome. Endocrinology. 1996;137:5250-5254.
26. Tezuka H, Eguchi K, Fukuda T, et al. Natural killer and natural killer-like cell activity of peripheral blood and intrathyroidal mononuclear cells from patients with Graves' disease. J Clin Endocrinol Metab. 1988;66:702-707.
27. Totterman TH, Andersson LC, Hayry P. Evidence for thyroid antigen-reactive T lymphocytes infiltrating the thyroid gland in Graves' disease. Clin Endocrinol (Oxf). 1979;11:59-68.
28. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997;275:960-963.
29. Mitsiades N, Poulaki V, Kotoula V, et al. Fas/Fas ligand upregulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1998;83:2199-2203.
30. Hammond LJ, Lowdell MW, Cerrano PG, et al. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. J Pathol. 1997;182:138-144.
31. Tourneur L, Damotte D, Marion S, et al. IL-10 is necessary for FasL-induced protection from experimental autoimmune thyroiditis but not for FasL-induced immune deviation. Eur J Immunol. 2002;32:1292-1299.
32. Stassi G, Di Liberto D, Todaro M, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol. 2000;1:483-488.
33. Mitsiades N, Poulaki V, Mitsiades CS, et al. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab. 2001;12:384-390.
34. Aust G, Scherbaum WA. Expression of cytokines in the thyroid: thyrocytes as potential cytokine producers. Exp Clin Endocrinol Diabetes. 1996;104(suppl 4):64-67.
35. Gianoukakis AG, Martino LJ, Horst N, et al. Cytokine-induced lymphocyte chemoattraction from cultured human thyrocytes: evidence for interleukin-16 and regulated upon activation, normal T cell expressed, and secreted expression. Endocrinology. 2003;144:2856-2864.
36. + T cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage. J Immunol. 1995;155:2902-2910.
37. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES [letter]. Nature. 1990;347:669-671.
38. Smith TJ, Sciaky D, Phipps RP, et al. CD40 expression in human thyroid tissue: Evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid. 1999;9:749-755.
39. Metcalfe RA, McIntosh RS, Marelli-Berg F, et al. Detection of CD40 on human thyroid follicular cells: analysis of expression and function. J Clin Endocrinol Metab. 1998;83:1268-1274.
40. Ajjan RA, Watson PF, Weetman AP. Cytokines and thyroid function. Adv Neuroimmunol. 1996;6:359-386.
41. Rasmussen AK. Cytokine actions on the thyroid gland. Dan Med Bull. 2000;47:94-114.
42. 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J Clin Endocrinol Metab. 1990;70:1735-1743.
43. 125I incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab. 1993;77:1439-1441.
44. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid. 1997;7:891-896.
45. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445-1448.
46. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101:482-487.
47. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf). 1996;44:635-642.
48. Schwartzentruber DJ, White DE, Zweig MH, et al. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer. 1991;68:2384-2390.
49. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132:5187-593.
50. Fentiman IS, Balkwill FR, Thomas BS, et al. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988;24:1299-1303.
51. Smith TJ. Fibroblast biology in thyroid diseases. Curr Opinion Endocrinol Diabetes. 2002;9:393-400.
52. + and specifically recognize autologous fibroblasts. J Clin Invest. 1994;93:2738-2743.
53. de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab. 1993;77:1120-1124.
54. Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 1993;23:10-17.
55. Berenson CS, Smith TJ. Human orbital fibroblasts in culture express ganglioside profiles distinct from those in dermal fibroblasts. J Clin Endocrinol Metab. 1995;80:2668-2674.
56. Smith TJ, Kottke RJ, Lum H, et al. Human orbital fibroblasts in culture bind and respond to endothelin. Am J Physiol. 1993;265:C138-C142.
57. Young DA, Evans CH, Smith TJ. Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci U S A. 1998;95:8904-8909.
58. Wang H-S, Cao HJ, Winn VD, et al. Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. J Biol Chem. 1996;271:22718-22728.
59. Smith TJ, Wang H-S, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995;268:C382-C388.
60. 2 synthase expression. J Biol Chem. 2002;277:16355-16364.
61. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today. 1991;12:349-352.
62. Spicer AP, Kaback LA, Smith TJ, et al. Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem. 1998;273:25117-25124.
63. Kaback LA, Smith TJ. Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1β in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1999;84:4079-4084.
64. Sempowski GD, Rozenblit J, Smith TJ, et al. Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998;274:C707-C714.
65. Cao HJ, Wang H-S, Zhang Y, et al. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:29615-29625.
66. Smith TJ, Sempowski GD, Wang H-S, et al. Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. J Clin Endocrinol Metab. 1995;80:2620-2625.
67. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385-392.
68. - subpopulations exhibit distinct phenotypes. Eur J Immunol. 2002;32:477-485.
69. Sciaky D, Brazer W, Center DM, et al. Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3-dependent mechanism. J Immunol. 2000;164:3806-3814.
70. Pritchard J, Horst N, Cruikshank W, et al. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942-950.
71. Pritchard J, Han R, Horst N, et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol. 2003;170:6348-6354.
72. Reddy S, Young M. IL-1β expression in islet cells of the NOD mouse and its spatial relationship to beta cells and inducible nitric oxide synthase. Ann N Y Acad Sci. 2002;958:190-193.
73. Mandrup-Poulsen T, Helqvist S, Wogensen LD, et al. Cytokine and free radicals as effector molecules in the destruction of pancreatic beta cells. Curr Top Microbiol Immunol. 1990;164:169-193.
74. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 1994;43:613-621.
75. Almawi WY, Tamim H, Azar ST. T helper type 1 and 2 cytokines mediate the onset and progression of type 1 (insulin-dependent) diabetes. J Clin Endocrinol Metab. 1999;84:1497-1502.
76. Rabinovitch A. Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev. 1993;1:215-240.
77. Ling Z, In't Veld PA, Pipeleers DG. Interaction of interleukin-1 with islet beta-cells. Distinction between indirect, aspecific cytotoxicity and direct, specific functional suppression. Diabetes. 1993;42:56-65.
78. Sarvetnick N, Shizuru J, Liggitt D, et al. Loss of pancreatic islet tolerance induced by B-cell expression of interferon-γ [letter]. Nature. 1990;346:844-847.
79. Campbell IL, Kay TW, Oxbrow L, et al. Essential role for interferon-γ and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest. 1991;87:739-742.
80. Debray-Sachs M, Carnaud C, Boitard C, et al. Prevention of diabetes in NOD mice treated with antibody to murine INF-γ. J Autoimmun. 1991;4:237-248.
81. Nicoletti F, Meroni PL, Landolfo S, et al. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-γ [letter]. Lancet. 1990;336:319.
82. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man-macrophages, lymphocytes, and interferon-γ containing cells. J Pathol. 1991;165:97-103.
83. Hultgren B, Huang X, Dybdal N, et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes. 1996;45:812-817.
84. Yang XD, Tisch R, Singer SM, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med. 1994;180:995-1004.
85. Grewal IS, Grewal KD, Wong FS, et al. Local expression of transgene encoded TNFα in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med. 1996;184:1963-1974.
86. Stewart TA, Hultgren B, Huang X, et al. Induction of type I diabetes by interferon-α in transgenic mice. Science. 1993;260:1942-1946.
87. Brod SA, Malone M, Darcan S, et al. Ingested interferon α suppresses type I diabetes in non-obese diabetic mice. Diabetologia. 1998;41:1227-1232.
88. Brod SA, Atkinson M, Lavis VR, et al. Ingested INF-α preserves residual β cell function in type 1 diabetes. J Interferon Cytokine Res. 2001;21:1021-1030.
89. Trembleau S, Penna G, Bosi E, et al. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med. 1995;181:817-821.
90. Trembleau S, Penna G, Gregori S, et al. Early Th1 response in unprimed nonobese diabetic mice to the tyrosine phosphatase-like insulinoma-associated protein 2, an autoantigen in type 1 diabetes. J Immunol. 2000;165:6748-6755.
91. 2. Diabetologia. 1997;40:641-646.
92. Trembleau S, Penna G, Gregori S, et al. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol. 1997;27:2330-2339.
93. Nitta Y, Kawamoto S, Tashiro F, et al. IL-12 plays a pathologic role at the inflammatory loci in the development of diabetes in NOD mice. J Autoimmun. 2001;16:97-104.
94. Trembleau S, Penna G, Gregori S, et al. Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. J Immunol. 1999;163:2960-2968.
95. Allison J, Oxbrow L, Miller JF. Consequences of in situ production of IL-2 for islet cell death. Int Immunol. 1994;6:541-549.
96. Ohashi PS, Oehen S, Aichele P, et al. Induction of diabetes is influenced by the infectious virus and local expression of MHC class I and tumor necrosis factor-α. J Immunol. 1993;150:5185-5194.
97. Guerder S, Picarella DE, Linsley PS, et al. Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor α leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A. 1994;91:5138-5142.
98. Picarella DE, Kratz A, Li C-B, et al. Insulitis in transgenic mice expressing tumor necrosis factor β (lymphotoxin) in the pancreas. Proc Natl Acad Sci U S A. 1992;89:10036-10040.
99. Jacob CO, Aiso S, Michie SA, et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin-1. Proc Natl Acad Sci U S A. 1990;87:968-972.
100. Serreze DV, Hamaguchi K, Leiter EH. Immunostimulation circumvents diabetes in NOD/Lt mice. J Autoimmun. 1989;2:759-776.
101. Zielasek J, Burkart V, Naylor P, et al. Interleukin-2-dependent control of disease development in spontaneously diabetic 1313 rats. Immunology. 1990;69:209-214.
102. Satoh J, Seino H, Abo T, et al. Recombinant human tumor necrosis factor-α suppresses autoimmune diabetes in nonobese diabetic mice. J Clin Invest. 1989;84:1345-1348.
103. Satoh J, Seino H, Shintani S, et al. Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-α. J Immunol. 1990;145:1395-1399.
104. Seino H, Takahashi K, Satoh J, et al. Prevention of autoimmune diabetes with lymphotoxin in NOD mice. Diabetes. 1993;42:398-404.
105. Takahashi K, Satoh J, Seino H, et al. Prevention of type I diabetes with lymphotoxin in BB rats. Clin Immunol Immunopathol. 1993;69:318-323.
106. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 1996;184:1093-1099.
107. Mueller R, Bradley LM, Krahl T, et al. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity. 1997;7:411-418.
108. Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med. 1994;179:1379-1384.
109. Moritani M, Yoshimoto K, Tashiro F, et al. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol. 1994;6:1927-1936.
110. Yang Z, Chen M, Wu R, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol. 2002;168:6479-6485.
111. Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol. 1994;71:169-175.
112. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
113. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111-2119.
114. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
115. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-α function [letter]. Nature. 1997;389:610-614.
116. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-α-mediated insulin resistance in genetic obesity. Endocrinology. 1998;139:4832-4838.
117. Feinstein R, Kanety H, Papa MZ, et al. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993;268:26055-26058.
118. Guo D, Donner DB. Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem. 1996;271:615-618.
119. Kanety H, Feinstein R, Papa MZ, et al. Tumor necrosis factor α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 1995;270:23780-23784.
120. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem. 1997;272:971-976.
121. Ruan H, Hacohen N, Golub TR, et al. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes. 2002;51:1319-1336.
122. Grunfeld C, Feingold KR. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991;3:143-158.
123. Ohsumi J, Sakakibara S, Yamaguchi J, et al. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells. Endocrinology. 1994;135:2279-2282.
124. Szalkowski D, White-Carrington S, Berger J, et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor α on differentiation, insulin-stimulated glucose uptake and gene expression in 3T3-L1 cells. Endocrinology. 1995;136:1474-1481.
125. Souza SS, Yamamoto MT, Franciosa MD, et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor α: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes. 1998;47:691-695.
126. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor α-induced inhibition of insulin signaling. J Clin Invest. 1997;100:1863-1869.
127. Katsuki A, Sumida Y, Murata K, et al. Troglitazone reduces plasma levels of tumour necrosis factor-α in obese patients with type 2 diabetes. Diabetes Obes Metab. 2000;2:189-191.
128. Ofei F, Hurel S, Newkirk J, et al. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996;45:881-885.
129. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6 but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82:4196-4200.
130. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interkeukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286-1292.
131. Bastard J-P, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338-3342.
132. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-334.
133. Bastard J-P, Maachi M, Tran Van Nhieu J, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002;87:2084-2089.
134. Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 1997;82:4167-4170.
135. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241-1248.
136. Rakasz E, Gal A, Biro J, et al. Modulation of glucocorticosteroid binding in human lymphoid, monocytoid and hepatoma cell lines by inflammatory cytokines interleukin (IL)-1 beta, IL-6 and tumour necrosis factor (TNF)-alpha. Scand J Immunol. 1993;37:684-689.
137. Dovio A, Masera RG, Sartori ML, et al. Autocrine up-regulation of glucocorticoid receptors by interleukin-6 in human osteoblast-like cells. Calcif Tissue Int. 2001;69:293-298.
138. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115-137.
139. Girasole G, Passeri G, Jilka RL, et al. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516-1524.
140. Greenfield EM, Shaw SM, Gornik SA, et al. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest. 1995;96:1238-1244.
141. Girasole G, Jilka RL, Passeri G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992;89:883-891.
142. Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. Cell. 1993;74:587-590.
143. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120-1126.
144. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci. 1998;840:194-204.
145. Kurihara N, Civin C, Roodman GD. Osteotropic factor responsiveness of highly purified populations of early and late precursors for human multinucleated cells expressing the osteoclast phenotype. J Bone Miner Res. 1991;6:257-261.
146. Taguchi Y, Yamamoto M, Yamate T, et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians. 1998;110:559-574.
147. Udagawa N, Takahashi N, Katagiri T, et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 1995;182:1461-1468.
148. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 1992;257:88-91.
149. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 1994;13:1189-1196.
150. Bellido T, Borba VZC, Roberson P, et al. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology. 1997;138:3666-3676.
151. Lin S-C, Yamate T, Taguchi Y, et al. Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. J Clin Invest. 1997;100:1980-1990.
152. Bismar H, Diel I, Ziegler R, et al. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab. 1995;80:3351-3355.
153. Masiukiewicz US, Mitnick M, Gulanski BI, et al. Evidence that the IL-6/IL-6 soluble receptor cytokine system plays a role in the increased skeletal sensitivity to PTH in estrogen-deficient women. J Clin Endocrinol Metab. 2002;87:2892-2898.
154. Cantatore FP, Loverro G, Ingrosso AM, et al. Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause. Clin Rheumatol. 1995;14:157-160.
155. Gregory MS, Duffner LA, Faunce DE, et al. Estrogen mediates the sex difference in post-burn immunosuppression. J Endocrinol. 2000;164:129-138.
156. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305-311.
157. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993;90:11924-11928.
158. Hughes DE, Brendan BF. Estrogen, transforming growth factor-beta, and the regulation of bone metabolism in health and disease. Endocrinologist. 1998;8:55-61.
159. Hughes DE, Dai A, Tiffee JC, et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2:1132-1136.
160. Rickard D, Russell G, Gowen M. Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos Int. 1992;2:94-102.
161. Wang X, Schwartz Z, Yaffe P, et al. The expression of transforming growth factor-beta and interleukin-1beta mRNA and the response to 1,25(OH)2D3′ 17 beta-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro. Endocrine. 1999;11:13-22.
162. Pacifici R, Rifas L, McCracken R, et al. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A. 1989;86:2398-2402.
163. Sunyer T, Lewis J, Collin-Osdoby P, et al. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest. 1999;103:1409-1418.
164. Kitazawa R, Kimble RB, Vannice JL, et al. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J Clin Invest. 1994;94:2397-2406.
165. Kimble RB, Matayoshi AB, Vannice JL, et. al. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinol. 1995;136:3054-3061.
166. Grey A, Mitnick MA, Shapses S, et al. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-a clinical research center study. J Clin Endocrinol Metab. 1996;81:3450-3454.
167. Li NH, Ouchi Y, Okamoto Y, et al. Effect of parathyroid hormone on release of interleukin 1 and interleukin 6 from cultured mouse osteoblastic cells. Biochem Biophys Res Commun. 1991;179:236-242.
168. Elias JA, Tang W, Horowitz MC. Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology. 1995;136:489-498.